Leerink Partnrs Issues Optimistic Estimate for BBIO Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Leerink Partnrs increased their Q2 2025 EPS estimates for shares of BridgeBio Pharma in a note issued to investors on Tuesday, July 15th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.69) per share for the quarter, up from their prior estimate of ($0.71). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($2.72) EPS, FY2026 earnings at ($1.58) EPS, FY2027 earnings at $0.32 EPS and FY2028 earnings at $3.15 EPS.

Other research analysts have also recently issued reports about the stock. Jefferies Financial Group assumed coverage on shares of BridgeBio Pharma in a report on Monday, July 14th. They set a “buy” rating and a $70.00 target price on the stock. Scotiabank raised their target price on shares of BridgeBio Pharma from $52.00 to $55.00 and gave the company a “sector outperform” rating in a research report on Wednesday, April 30th. Wells Fargo & Company raised their target price on shares of BridgeBio Pharma from $67.00 to $76.00 and gave the company an “overweight” rating in a research report on Monday, June 30th. Wall Street Zen upgraded shares of BridgeBio Pharma from a “sell” rating to a “hold” rating in a report on Saturday, June 7th. Finally, HC Wainwright lifted their price target on shares of BridgeBio Pharma from $53.00 to $56.00 and gave the stock a “buy” rating in a report on Monday, June 9th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, BridgeBio Pharma has an average rating of “Moderate Buy” and an average target price of $61.20.

BridgeBio Pharma Trading Down 0.5%

Shares of BBIO opened at $46.51 on Thursday. BridgeBio Pharma has a 12 month low of $21.72 and a 12 month high of $48.68. The firm’s 50 day moving average is $39.79 and its 200-day moving average is $35.91. The stock has a market capitalization of $8.83 billion, a PE ratio of -13.18 and a beta of 1.15.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million during the quarter, compared to the consensus estimate of $57.14 million. The firm’s revenue was down 44.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.20) earnings per share.

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $42.54, for a total value of $1,701,600.00. Following the transaction, the chief executive officer owned 975,686 shares of the company’s stock, valued at approximately $41,505,682.44. This trade represents a 3.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Global Investors Lp Viking sold 3,500,000 shares of the business’s stock in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $44.00, for a total value of $154,000,000.00. Following the sale, the insider directly owned 18,555,375 shares of the company’s stock, valued at $816,436,500. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 9,926,181 shares of company stock valued at $375,528,164. 18.20% of the stock is owned by insiders.

Institutional Investors Weigh In On BridgeBio Pharma

A number of institutional investors have recently added to or reduced their stakes in BBIO. Farallon Capital Management LLC grew its position in shares of BridgeBio Pharma by 140.1% during the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company’s stock valued at $115,111,000 after acquiring an additional 2,448,000 shares during the period. Driehaus Capital Management LLC purchased a new stake in BridgeBio Pharma in the 1st quarter worth approximately $51,874,000. Invesco Ltd. lifted its stake in BridgeBio Pharma by 147.0% in the 1st quarter. Invesco Ltd. now owns 2,206,163 shares of the company’s stock worth $76,267,000 after purchasing an additional 1,313,036 shares in the last quarter. Woodline Partners LP increased its holdings in shares of BridgeBio Pharma by 132.9% in the 4th quarter. Woodline Partners LP now owns 2,211,521 shares of the company’s stock worth $60,684,000 after buying an additional 1,261,772 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of BridgeBio Pharma by 4,544.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,120,933 shares of the company’s stock worth $38,751,000 after buying an additional 1,096,799 shares during the last quarter. 99.85% of the stock is owned by institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.